Compare Adaptive Biotechnologies Corp (ADPT) vs First Citizens BancShares Inc (FCNCA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs First Citizens BancShares Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while First Citizens BancShares Inc trades at $2,045.06 (market cap $23.94B). The key difference: First Citizens BancShares Inc is far larger — about 7.2× Adaptive Biotechnologies Corp's market cap, and First Citizens BancShares Inc pays a 0.4% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | FCNCA | |
|---|---|---|
Market Cap | $3.33B | $23.94B |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $2.20K |
52-Week Low | $10.24 | $1.64K |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
First Citizens BancShares (FCNCA) trades at $2,117.35, up 1.65% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamental health with a P/E of 12.21 and net income margin of 24.35%, supported by consecutive earnings beats including Q1 2026 EPS of $44.86 versus $39.56 expected. Recent corporate developments include the planned rebranding of Silicon Valley Bank and expansion of commercial banking capabilities.
The outlook remains positive given earnings momentum and analyst consensus price target of $2,320, though risks include margin pressure and credit exposure from the SVB integration. Upside potential hinges on continued execution amid a competitive banking landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →
